Standard Chem & Pharm CO., LTD. (1720.TW)
TWD 61.0
(-2.09%)
TWD 61.0
(-2.09%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.05 Billion TWD | -13.62% |
| 2022 | 3.53 Billion TWD | 6.91% |
| 2021 | 3.3 Billion TWD | 54.15% |
| 2020 | 2.14 Billion TWD | -6.05% |
| 2019 | 2.28 Billion TWD | 4.05% |
| 2018 | 2.19 Billion TWD | 0.96% |
| 2017 | 2.17 Billion TWD | 7.04% |
| 2016 | 2.02 Billion TWD | 6.33% |
| 2015 | 1.9 Billion TWD | 7.88% |
| 2014 | 1.76 Billion TWD | -0.1% |
| 2013 | 1.77 Billion TWD | -2.54% |
| 2012 | 1.81 Billion TWD | 4.17% |
| 2011 | 1.74 Billion TWD | 8.65% |
| 2010 | 1.6 Billion TWD | 55.1% |
| 2009 | 1.03 Billion TWD | 9.71% |
| 2008 | 943.47 Million TWD | 29.84% |
| 2007 | 726.66 Million TWD | -20.31% |
| 2006 | 911.85 Million TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 3.52 Billion TWD | 15.48% |
| 2024 Q2 | 3.09 Billion TWD | -12.16% |
| 2023 Q4 | 3.05 Billion TWD | -2.41% |
| 2023 FY | 3.05 Billion TWD | -13.62% |
| 2023 Q1 | 3.86 Billion TWD | 9.35% |
| 2023 Q2 | 3.71 Billion TWD | -3.78% |
| 2023 Q3 | 3.12 Billion TWD | -15.88% |
| 2022 Q2 | 4 Billion TWD | 15.9% |
| 2022 FY | 3.53 Billion TWD | 6.91% |
| 2022 Q4 | 3.53 Billion TWD | -11.84% |
| 2022 Q3 | 4 Billion TWD | 0.13% |
| 2022 Q1 | 3.45 Billion TWD | 4.5% |
| 2021 Q1 | 2.15 Billion TWD | 0.69% |
| 2021 FY | 3.3 Billion TWD | 54.15% |
| 2021 Q3 | 2.26 Billion TWD | -5.47% |
| 2021 Q4 | 3.3 Billion TWD | 45.71% |
| 2021 Q2 | 2.39 Billion TWD | 11.15% |
| 2020 Q3 | 2.1 Billion TWD | -4.91% |
| 2020 FY | 2.14 Billion TWD | -6.05% |
| 2020 Q1 | 2.53 Billion TWD | 11.24% |
| 2020 Q4 | 2.14 Billion TWD | 1.68% |
| 2020 Q2 | 2.21 Billion TWD | -12.64% |
| 2019 Q4 | 2.28 Billion TWD | -11.13% |
| 2019 FY | 2.28 Billion TWD | 4.05% |
| 2019 Q3 | 2.56 Billion TWD | 6.19% |
| 2019 Q2 | 2.41 Billion TWD | 4.88% |
| 2019 Q1 | 2.3 Billion TWD | 5.12% |
| 2018 FY | 2.19 Billion TWD | 0.96% |
| 2018 Q4 | 2.19 Billion TWD | 1.47% |
| 2018 Q3 | 2.16 Billion TWD | -8.34% |
| 2018 Q2 | 2.35 Billion TWD | 13.31% |
| 2018 Q1 | 2.08 Billion TWD | -4.21% |
| 2017 Q2 | 2.23 Billion TWD | 18.64% |
| 2017 Q4 | 2.17 Billion TWD | 3.13% |
| 2017 FY | 2.17 Billion TWD | 7.04% |
| 2017 Q3 | 2.1 Billion TWD | -5.77% |
| 2017 Q1 | 1.88 Billion TWD | -7.16% |
| 2016 FY | 2.02 Billion TWD | 6.33% |
| 2016 Q2 | 2.02 Billion TWD | 9.52% |
| 2016 Q3 | 1.96 Billion TWD | -2.81% |
| 2016 Q4 | 2.02 Billion TWD | 3.01% |
| 2016 Q1 | 1.85 Billion TWD | -3.03% |
| 2015 Q1 | 1.65 Billion TWD | -6.32% |
| 2015 Q4 | 1.9 Billion TWD | 14.12% |
| 2015 FY | 1.9 Billion TWD | 7.88% |
| 2015 Q3 | 1.67 Billion TWD | -6.1% |
| 2015 Q2 | 1.78 Billion TWD | 7.47% |
| 2014 FY | 1.76 Billion TWD | -0.1% |
| 2014 Q4 | 1.76 Billion TWD | -7.15% |
| 2014 Q3 | 1.9 Billion TWD | -9.04% |
| 2014 Q2 | 2.09 Billion TWD | 22.47% |
| 2014 Q1 | 1.71 Billion TWD | -3.42% |
| 2013 Q2 | 1.83 Billion TWD | -7.4% |
| 2013 Q1 | 1.97 Billion TWD | 8.94% |
| 2013 FY | 1.77 Billion TWD | -2.54% |
| 2013 Q3 | 1.55 Billion TWD | -15.18% |
| 2013 Q4 | 1.77 Billion TWD | 13.9% |
| 2012 Q3 | 1.56 Billion TWD | -8.84% |
| 2012 Q1 | 1.49 Billion TWD | -14.2% |
| 2012 FY | 1.81 Billion TWD | 4.17% |
| 2012 Q4 | 1.81 Billion TWD | 16.07% |
| 2012 Q2 | 1.71 Billion TWD | 14.75% |
| 2011 Q1 | 1.61 Billion TWD | 0.44% |
| 2011 Q4 | 1.74 Billion TWD | 11.41% |
| 2011 Q3 | 1.56 Billion TWD | -8.26% |
| 2011 Q2 | 1.7 Billion TWD | 5.83% |
| 2011 FY | 1.74 Billion TWD | 8.65% |
| 2010 FY | 1.6 Billion TWD | 55.1% |
| 2010 Q4 | 1.6 Billion TWD | 0.0% |
| 2009 FY | 1.03 Billion TWD | 9.71% |
| 2008 FY | 943.47 Million TWD | 29.84% |
| 2007 FY | 726.66 Million TWD | -20.31% |
| 2006 FY | 911.85 Million TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Grape King Bio Ltd | 3.88 Billion TWD | 21.395% |
| Maywufa Company Ltd. | 794.91 Million TWD | -283.863% |
| ScinoPharm Taiwan, Ltd. | 1.35 Billion TWD | -124.837% |
| Lotus Pharmaceutical Co., Ltd. | 15.65 Billion TWD | 80.512% |
| LIWANLI Innovation Co., Ltd. | 50.66 Million TWD | -5923.267% |
| YungShin Global Holding Corporation | 3.59 Billion TWD | 15.18% |
| PhytoHealth Corporation | 79.84 Million TWD | -3721.447% |
| SCI Pharmtech, Inc. | 1.59 Billion TWD | -91.816% |
| Formosa Laboratories, Inc. | 5.42 Billion TWD | 43.763% |
| PharmaEssentia Corporation | 3.32 Billion TWD | 8.123% |
| Bora Pharmaceuticals Co., LTD. | 13.28 Billion TWD | 77.033% |